Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Follow-Up Questions
Who is the CEO of Oxford Nanopore Technologies PLC?
Dr. Gurdial Sanghera is the Chief Executive Officer of Oxford Nanopore Technologies PLC, joining the firm since 2005.
What is the price performance of ONTTF stock?
The current price of ONTTF is $1.81, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Oxford Nanopore Technologies PLC?
Oxford Nanopore Technologies PLC belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Oxford Nanopore Technologies PLC market cap?
Oxford Nanopore Technologies PLC's current market cap is $1.7B
Is Oxford Nanopore Technologies PLC a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Oxford Nanopore Technologies PLC, including 5 strong buy, 11 buy, 3 hold, 1 sell, and 5 strong sell
